In the Valsartan in Acute Myocardial Infarction Trial (VALIANT), hypotension in post-myocardial infarction patients led to permanent discontinuation of therapy in 1.4% of valsartan-treated patients and 0.8% of captopril-treated patients
In Indian clinical settings, factors such as diverse patient populations, varying disease severity, and healthcare accessibility influence treatment decisions
Daily supplementation as low as 250 mg of Setria achieved increased glutathione levels in blood and erythrocytes
With regular use, it might support clearer skin, better energy levels, and overall vitality, making it a complete daily wellness supplement
This week on the You Are Not Broken podcast episode #329, I sat down with the powerhouse that is Dr
For protocols that value regulatory-grade evidence depth and a settled safety label, tirzepatide remains the reference molecule